Overview
ARMP market data
Price History
ARMP price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.80 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.38 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -5,432.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.39 – $16.34 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $176.2M · P/B 1.24 · P/S 33.87.
Company News
Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K EstimateBenzinga · Aug 12, 2026, 8:29 PM
Armata Pharmaceuticals Announces Promotion Of David House To CFOBenzinga · Aug 12, 2026, 8:14 PM
Why Is Armata Pharma Stock Gaining Monday?Benzinga · Jul 20, 2026, 4:45 PM
Armata Pharmaceuticals shares are trading higher after the company reported clinical, regulatory, manufacturing, and operational progress advancing AP‑SA02 toward a planned Phase 3 study in complicated Staphylococcus aureus bacteremia.Benzinga · Jul 20, 2026, 2:35 PM
Armata Pharma Promotes David House To CFOBenzinga · Jul 20, 2026, 11:13 AM
8-K filing — Armata Pharmaceuticals, Inc. (ARMP)SEC EDGAR · Jul 20, 2026, 11:13 AM
Armata Announces Significant Clinical, Regulatory, Manufacturing And Operational Progress Supporting Advancement Of AP-SA02 Toward Planned Phase 3 Superiority Study For Adjunct Treatment Of Complicated BacteremiaBenzinga · Jul 20, 2026, 11:12 AM
Armata Pharma Receives Agreement From FDA On Agreed Initial Pediatric Study PlanBenzinga · Jul 13, 2026, 11:14 AM
8-K/A filing — Armata Pharmaceuticals, Inc. (ARMP)SEC EDGAR · Jun 24, 2026, 8:19 PM
Armata Pharma Receives Additional $2.5M Of Non-Dilutive DoD Funding Via Medical Technology Enterprise Consortium, Managed By Naval Medical Research CommandBenzinga · Jun 23, 2026, 11:20 AM